Microbiota and metabolic dysfunction associated with steatotic liver disease
Disease progression in metabolic dysfunction-associated steatotic liver disease (MASLD) is driven by multiple mechanisms that act together in genetically predisposed subjects. Amongst others, the gut-liver axis plays a crucial role in the development and progression of MASLD. This inevitably involve...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Verduci Editore
2024-09-01
|
| Series: | Microbiota in Health and Disease |
| Subjects: | |
| Online Access: | https://www.microbiotajournal.com/wp-content/uploads/sites/7/2024/09/e1115.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841560917232320512 |
|---|---|
| author | Q. Zhu S. Francque W. Kwanten |
| author_facet | Q. Zhu S. Francque W. Kwanten |
| author_sort | Q. Zhu |
| collection | DOAJ |
| description | Disease progression in metabolic dysfunction-associated steatotic liver disease (MASLD) is driven by multiple mechanisms that act together in genetically predisposed subjects. Amongst others, the gut-liver axis plays a crucial role in the development and progression of MASLD. This inevitably involves the microbiome. The exact impact of the microbiome on MASLD is not yet fully understood, but the imbalance in gut microbiota (GM) can cause altered integrity of the intestinal epithelium, increased permeability of the intestinal barrier, and various harmful substances and metabolites secreted by the GM reaching the liver. The gut and liver interact bidirectionally through multiple molecules and products, such as nutrients, microbial antigens, metabolites, and bile acids (BAs), which affect both metabolism and immunity, thus controlling both gastrointestinal and liver health and disease. Understanding the factors that shape microbiome complexity may help improve prevention, diagnosis, and treatment in a precise and personalized manner. This review focuses on the recent data on the etiopathogenesis of MASLD linked to the gastrointestinal microbiome and looks critically into the research methods that should aim at comprehensively and accurately reflecting the true status of the GM. |
| format | Article |
| id | doaj-art-b7d0eaeca1194f6faac8a916c34197d6 |
| institution | Kabale University |
| issn | 2704-8845 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | Verduci Editore |
| record_format | Article |
| series | Microbiota in Health and Disease |
| spelling | doaj-art-b7d0eaeca1194f6faac8a916c34197d62025-01-03T10:30:12ZengVerduci EditoreMicrobiota in Health and Disease2704-88452024-09-01610.26355/mhd_20249_11151115Microbiota and metabolic dysfunction associated with steatotic liver diseaseQ. Zhu0S. Francque1W. Kwanten2Department of Gastroenterology Hepatology, Antwerp University Hospital, Antwerp, BelgiumDepartment of Gastroenterology Hepatology, Antwerp University Hospital, Antwerp, BelgiumDepartment of Gastroenterology Hepatology, Antwerp University Hospital, Antwerp, BelgiumDisease progression in metabolic dysfunction-associated steatotic liver disease (MASLD) is driven by multiple mechanisms that act together in genetically predisposed subjects. Amongst others, the gut-liver axis plays a crucial role in the development and progression of MASLD. This inevitably involves the microbiome. The exact impact of the microbiome on MASLD is not yet fully understood, but the imbalance in gut microbiota (GM) can cause altered integrity of the intestinal epithelium, increased permeability of the intestinal barrier, and various harmful substances and metabolites secreted by the GM reaching the liver. The gut and liver interact bidirectionally through multiple molecules and products, such as nutrients, microbial antigens, metabolites, and bile acids (BAs), which affect both metabolism and immunity, thus controlling both gastrointestinal and liver health and disease. Understanding the factors that shape microbiome complexity may help improve prevention, diagnosis, and treatment in a precise and personalized manner. This review focuses on the recent data on the etiopathogenesis of MASLD linked to the gastrointestinal microbiome and looks critically into the research methods that should aim at comprehensively and accurately reflecting the true status of the GM.https://www.microbiotajournal.com/wp-content/uploads/sites/7/2024/09/e1115.pdfmicrobiotamasldmethodologytreatment. |
| spellingShingle | Q. Zhu S. Francque W. Kwanten Microbiota and metabolic dysfunction associated with steatotic liver disease Microbiota in Health and Disease microbiota masld methodology treatment. |
| title | Microbiota and metabolic dysfunction associated with steatotic liver disease |
| title_full | Microbiota and metabolic dysfunction associated with steatotic liver disease |
| title_fullStr | Microbiota and metabolic dysfunction associated with steatotic liver disease |
| title_full_unstemmed | Microbiota and metabolic dysfunction associated with steatotic liver disease |
| title_short | Microbiota and metabolic dysfunction associated with steatotic liver disease |
| title_sort | microbiota and metabolic dysfunction associated with steatotic liver disease |
| topic | microbiota masld methodology treatment. |
| url | https://www.microbiotajournal.com/wp-content/uploads/sites/7/2024/09/e1115.pdf |
| work_keys_str_mv | AT qzhu microbiotaandmetabolicdysfunctionassociatedwithsteatoticliverdisease AT sfrancque microbiotaandmetabolicdysfunctionassociatedwithsteatoticliverdisease AT wkwanten microbiotaandmetabolicdysfunctionassociatedwithsteatoticliverdisease |